1134327-98-2 Usage
Description
7-Bromo-Imidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester is a heterocyclic organic chemical compound belonging to the imidazo-pyridine class. It features a pyridine ring fused to an imidazole ring, with a carboxylic acid ethyl ester group and a bromo substituent, endowing it with unique chemical properties. 7-BroMo-iMidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester serves as a potential precursor in chemical synthesis and holds promise for applications in pharmaceuticals, agrochemicals, and materials science due to its structural attributes.
Uses
Used in Pharmaceutical Industry:
7-Bromo-Imidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications, given its capacity to be modified and incorporated into diverse molecular frameworks.
Used in Agrochemical Industry:
In the agrochemical sector, 7-Bromo-Imidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester is utilized as a building block in the creation of novel agrochemicals. Its properties may contribute to the design of effective pesticides or herbicides, enhancing crop protection and yield.
Used in Materials Science:
7-Bromo-Imidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester is employed in materials science as a component in the development of new materials with specific properties. Its incorporation into polymers or other materials could lead to advancements in areas such as electronics, sensors, or specialty coatings,得益于其独特的化学结构和可修饰性。
(Note: The original instruction was to list the uses of Glycerol, but the provided materials were about 7-Bromo-Imidazo[1,2-a]pyridine-3-carboxylic acid ethyl ester. Therefore, the uses listed are for the latter compound based on the information given.)
Check Digit Verification of cas no
The CAS Registry Mumber 1134327-98-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,3,4,3,2 and 7 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1134327-98:
(9*1)+(8*1)+(7*3)+(6*4)+(5*3)+(4*2)+(3*7)+(2*9)+(1*8)=132
132 % 10 = 2
So 1134327-98-2 is a valid CAS Registry Number.
1134327-98-2Relevant articles and documents
Design, Synthesis, and Biological Evaluation of Imidazo[1,2- a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors
Yu, Ya'Nan,Han, Yuqiao,Zhang, Fupo,Gao, Zhenmei,Zhu, Tong,Dong, Suzhen,Ma, Mingliang
, p. 3028 - 3046 (2020/04/09)
PI3K-Akt-mTOR signaling pathway has been validated as an effective targeting pathway for cancer therapy. However, no PI3K/mTOR dual inhibitor has been approved by the FDA yet. Therefore, it is still essential to discover a candidate with good efficacy and low toxicity. In our design, a series of imidazo[1,2-a]pyridine derivatives had been synthesized and subjected to activity assessment in vitro and in vivo. 15a was proved to be a potent PI3K/mTOR dual inhibitor with excellent kinase selectivity, modest plasma clearance, and acceptable oral bioavailability. Besides, 15a displayed significant inhibition of tumor growth in HCT116 and HT-29 xenografts without obvious effect on body weight.
Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)
-
Paragraph 1722; 1727; 1728; 1729; 1730, (2019/06/07)
The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)
SOLID FORMS OF BICYCLIC HETEROCYCLIC DERIVATIVES AS PDGF RECEPTOR MEDIATORS
-
Page/Page column 40, (2014/09/16)
The present invention provides novel solid forms of pharmaceutically active agents and therapeutic uses thereof. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
